Aplastic Anemia: Presence in Human Bone Marrow of Cells That Suppress Myelopoiesis* (Thymus-Derived Lymphocytes/Suppressor Cells/Differentiation) WALT A

Total Page:16

File Type:pdf, Size:1020Kb

Aplastic Anemia: Presence in Human Bone Marrow of Cells That Suppress Myelopoiesis* (Thymus-Derived Lymphocytes/Suppressor Cells/Differentiation) WALT A Proc. Natl. Acad. Sci. USA Vol. 73, No. 8, pp.2890-2894*, August 1976 Medical Sciences Aplastic anemia: Presence in human bone marrow of cells that suppress myelopoiesis* (thymus-derived lymphocytes/suppressor cells/differentiation) WALT A. KAGAN, JoAo A. ASCENSAO, RAJENDRA N. PAHWA, JOHN A. HANSEN, GIDEON GOLDSTEIN, ELISA B. VALERA, GENEVIEVE S. INCEFY, MALCOLM A. S. MOORE, AND ROBERT A. GOOD Memorial Sloan-Kettering Cancer Center, New York, N.Y. 10021 Contributed by Robert A. Good, May 24, 1976 ABSTRACT Bone marrow from a patient with aplastic all negative. There was no history of exposure to drugs or anemia was shown by multiple criteria to have a block in early chemical agents known to be capable of producing aplastic myeloid differentiation. This block was overcome in vitro by anemia. elimination of marrow lymphocytes. Furthermore, this differ- entiation block was transferred in vitro to normal marrow by coculturing with the patient's marrow. We suggest that some METHODS cases of aplastic anemia may be due to an immunologically Cell Separation. Heparinized bone marrow was obtained based suppression of marrow cell differentiation rather than from the posterior iliac crest of the patient and normal adult to a defect in stem cells or their necessary inductive environ- donors in 10 to 20 separate 0.5-ml aspirations. The cells were ment. separated according to density differences by centrifugation The hematopoietic system in man is thought to develop from on a Ficoll-hypaque gradient by the method of Boyum (5). Cells a common stem cell analogous to the spleen colony forming unit present at the plasma/Ficoll-hypaque interface were collected, in mice (CFU-s) (1), which then differentiates into committed and this heterogeneous mixture was then separated according progenitor cells of the granulocytic and monocytic series to size by velocity sedimentation at unit gravity by the method (CFU-c) (2), megakaryocytic, lymphoid, and erythroid lines, of Miller and Phillips (6). and then passes through several more differentiation steps into Surface Markers. Complement receptors on cells were as- mature effector cells. Aplastic anemia is a disease characterized sayed by rosette formation with sheep erythrocytes (SRBC) by a marked decrease in the production of erythrocytes, leu- coated with antibody and complement (7). SRBC (Flow Labs) kocytes, and platelets. The etiology of this kind of bone marrow were incubated for 30 min at 370 with an equal volume of failure is complex, and about 50% of all cases are idiopathic. rabbit IgM antibody against SRBC (Cordis) diluted by 1So. There has been considerable speculation about the possible role These cells (EA) were then incubated 30 min at 370 with 1A of an immunologic mechanism in the pathogenesis of some volume of Swiss mouse serum as a source of nonlytic comple- cases (3, 4), but this mechanism has not yet been fully docu- ment. These cells (EAC) were washed twice and resuspended mented. We present here evidence for such a mechanism. to 2 X 108 cells per ml, and 50 Ml of EAC were incubated with 50 Ml of bone marrow cells at 3 X 106 cells per ml for 30 min at CASE REPORT 370. Three fields of 100 cells were counted in a hemocytometer, and cells were scored as positive if they bound four or more The patient was a 26-year-old white woman diagnosed as EAC. having aplastic anemia by bone marrow biopsy in July 1973 The number of thymus-derived (T) lymphocytes was de- after recurrent episodes of bruising. Therapeutic trials with termined by spontaneous rosette formation with SRBC (8). Fifty prednisone, testosterone, oxymethalone, folic acid, and pyri- microliters of bone marrow cells at 3 X 106 cells per ml were doxine did not result in any significant improvement in her mixed with 50 Ml of washed SRBC at 2 X 108 cells per ml and condition. 25 ,l of heat-inactivated SRBC-absorbed fetal calf serum. This The patient was referred to the Memorial Sloan-Kettering mixture was incubated for 5 min at 37?, centrifuged at 200 X Cancer Center in April 1975 as a candidate for bone marrow g for 5 min at 24°, and then incubated for 3-6 hr at 4°. Four transplantation. At that time her white cell count was 1500/ fields of 100 cells were counted in a hemocytometer, and cells mm3, with 65% lymphocytes, 30% neutrophils, and 5% mono were scored as positive if they bound four or more SRBC. cytes, and her platelet count was 10,000/mm3. Repeated bone Surface Marker Induction. Separated bone marrow cell marrow aspirations and biopsies showed marked hypocellula- fractions were incubated at 1.5 X 106 cells per ml in RPMI-1640 rity with 80% lymphocytes, 6% neutrophils, 5% immature containing 5% fetal calf serum for 8 hr at 37° in humidified 5% myeloid cells, 3% erythroid precursors, 5% monocytes, and an CO2 and 95% air. These cultures contained either medium absence of megakaryocytes. All medications were discontinued, alone (control), or ubiquitin (0.5 ,g/ml). After incubation, the and the patient remained clinically stable supported by trans- cells were washed twice, resuspended in RPMI-1640 to 3 X 106 fusions of frozen red blood cells and HLA matched platelets cells per ml, and assayed for surface markers. Ubiquitin was every 10 days. Screening tests for possible causes of the aplastic prepared as described (9). anemia, including the Ham test, sugar-water test, antinuclear Spontaneous DNA Synthesis. In the course of studying the antibody test, Coomb's test, and chest x-rays for thymoma, were response of marrow cells in mixed leukocyte culture, the spontaneous DNA synthesis of cells was measured by substi- Abbreviations: CFU-s, colony forming unit (spleen); CFU-c, colony irradiated marrow cells for irradiated allo- forming unit (culture); SRBC, sheep erythrocytes; T cell, thymus- tuting autologous derived lymphocyte. genic peripheral blood lymphocytes. * Part of this paper was presented at the American Society for Clinical Cells were resuspended at 1 X 106 cells per ml in RPMI-1640 Investigation meetings on May 3, 1976. with penicillin (50 units/ml), streptomycin (50 Mug/ml) and 15% 2890 Downloaded by guest on September 28, 2021 Medical Sciences: Kagan et al. Proc. Nati. Acad. Sci. USA 73 (1976) 2891 Table 1. Cellular composition of aplastic bone marrow separated (a) by Ficoll-hypaque centrifugation alone or (b) by Ficoll-hypaque centrifugation followed by velocity sedimentation la (b) 0 S. Sedimentation velocity x .0 (mm/hr) So u 0 Cell type (a) 6.8-4.1 3.8-3.4 3.2-2.8 0'. Lymphocyte 72% 17% 90% 100% Mature granulocyte 10% 34% 0% 0% Metamyelocyte 12% 12% 0% 0% Myelocyte 3% 6% 0% 0% Promyelocyte 0% 1% 0% 0% Normoblast 1% 18% 4% 0% mm/hr Monocyte 1% 6% 6% 0% Plasma cell 1% 4% 0% 0% FIG. 1. Distribution of nucleated cells in human bone marrow after separation first by Ficoll-hypaque centrifugation and then by Results are expressed as percent of all cells present in that velocity sedimentation. fraction. heat-inactivated pooled human AB serum. An aliquot of these 6 to 9 mm/hr, mainly promyelocytes, myelocytes, and me- was irradiated in a Cesium Gammacel 40 at 125 rad/min (1.25 tamyelocytes with a few myeloblasts, and erythroblasts. J/kg min) for 10 min for use as stimulator cells. Fifty microliters Fig. 1 also shows the distribution of cells in the marrow of the of responder marrow cells, 50 .ul of stimulator cells, and 100 /A patient with aplastic anemia. As expected, there was a striking of medium were placed in triplicate in round-bottom micro- deficit of cells in the mature and immature granulocyte regions plate wells (Cooke no. 1-221-24-1) and incubated for 96 hr at of this distribution. However, this separation technique sig- 370 in 5% CO2, 95% humidified air. Cells were labeled with nificantly enriched for the few mature and immature granu- 0.03 juCi of [14C]thymidine (New England Nuclear) for 24 hr locytes present in this patient's marrow. Table 1 gives the cel- and harvested; radioactivity was measured in a scintillation lular composition of the different regions of this distribution counter (Packard). The mean cpm of three wells is reported. and demonstrates that while granulocytes comprised only 25% CFU-c Assay. The assay for granulocyte-macrophage pro- of the marrow cells separated on a Ficoll-hypaque gradient, genitor cells (CFU-c) was performed by the method of Pike and 55% of the cells sedimenting from 4.1 to 6.8 mm/hr were Robinson (10) using feeder layers of normal human leukocytes granulocytes. Furthermore, velocity sedimentation reduced as a source of colony stimulating factors. Marrow cultures were the proportion of lymphocytes from 72% in the original marrow established at concentrations of 2 X 105 cells per ml, incubated separated on a Ficoll-hypaque gradient to only 17% in the for 7 days at 37° in 10% CO2 humidified air, and scanned for fraction sedimenting from 4.1 to 6.8 mm/hr. Tetrachrome- the presence of colonies consisting of more than 40 cells and stained cytocentrifuge preparations of patient's cells in each clusters of 3-40 cells under a dissecting microscope. of these regions are shown in Fig. 2. Marrow Cocultures. Marrow cells from the patient and two normal donors, which had been separated on a Ficoll-hypaque Elevated number of T lymphocytes in aplastic marrow gradient, were suspended at 1 X 106 cells per ml and were The distribution of cells bearing certain surface markers was mixed in equal proportions. The mixtures and original sus- next investigated. In normal adults, 17% of the cells in marrow pensions were then assayed as described above in the CFU-c assay.
Recommended publications
  • Severe Aplastic Anemia
    Severe AlAplas tic AiAnemia Monica S. Thakar, MD Pediatric BMT Medical College of Wisconsin Outline of Talk 1. Clinical description of aplastic anemia 2. Data collection forms And a couple of quizzes in between… CLINICAL DESCRIPTIONS What is aplastic anemia? • More than just anemia – Involves low counts in 2 of 3 cell lines: red blood cells (RBC), white blood cells (WBC), pltltlatelets • Should NOT involve dysplasia – EiException: RBC can sometimes be dlidysplastic • Should have NORMAL cytogenetics • If dysplasia (beyond RBCs) or abnormal cytogenetics seen, think myelodysplastic syndrome (MDS) What is “severe” aplastic anemia? • Marrow cellularity ≤25% AND • Two of the following peripheral blood features: – Absolute neutrophil count (ANC) < 0.5 x 109/L – Platelet count <20 x 109/L – Absolute reticulocyte count < 40 x 109/L • “Very” severe aplastic anemia – Same as above except ANC <0.2 x 109/L NORMAL BttBottom Li ne: Severely Reduced HtitiHematopoietic Stem Cell Precursors SEVERE APLASTIC ANEMIA IBIn Bone M arrow Epidemiology • Half of cases seen in first 3 decades of life • Incidence: – 2 cases/m illion in WtWestern countitries – 2‐3 fold higher in Asia • Ethnic predisposition: – Asian • Genetics vs different environmental exposures? • Sex predisposition: M:F is 1:1 Pathoppyhysiology : 3 Main Mechanisms Proposed 1. Immune‐mediated – HthiHypothesis: RdRevved‐up T cells dtdestroy stem cells – Observation: Immunosuppression improves blood counts 2. Stem‐cell “depletion” or “defect” – Hypothesis: Drugs or viruses directly destroy stem cells
    [Show full text]
  • December Is National Aplastic Anemia Awareness Month
    December Is National Aplastic Anemia Awareness Month What Is Aplastic Anemia? Aplastic anemia is a non-cancerous disease that occurs when the bone marrow stops making enough blood cells. The body makes three types of blood cells: red blood cells, which contain hemoglobin and deliver oxygen to all parts of the body white blood cells, which help fight infection platelets, which help blood clot when you bleed These blood cells are made in the bone marrow, which is the soft, sponge-like material found inside bones. The bone marrow contains immature cells called stem cells that produce blood cells. Stem cells grow into red cells, white cells, and platelets or they can make more stem cells. In patients who have aplastic anemia, there are not enough stem cells in the bone marrow to make enough blood cells. Picture of blood cells maturing from stem cells. Experts believe that aplastic anemia is an autoimmune disorder. This means that the patient’s immune system (which helps fight infection) reacts against the bone marrow and the bone marrow is not able to make blood cells. Stem cells are no longer being replaced and the left over stem cells are not working well. Therefore, the amount of red cells, white cells, and platelets begin to drop. If blood levels drop too low, a person can feel very tired (from low red cells), have bleeding or bruising (from low platelets), and/or have many or severe infections (from low white cells). What Are the Key Statistics About Aplastic Anemia? Aplastic anemia can occur in anyone of any age, race, or gender.
    [Show full text]
  • Trauma in the Aged Myelopoiesis Induced by Severe Shock And
    A Detailed Characterization of the Dysfunctional Immunity and Abnormal Myelopoiesis Induced by Severe Shock and Trauma in the Aged This information is current as of September 23, 2021. Dina C. Nacionales, Benjamin Szpila, Ricardo Ungaro, M. Cecilia Lopez, Jianyi Zhang, Lori F. Gentile, Angela L. Cuenca, Erin Vanzant, Brittany Mathias, Jeevan Jyot, Donevan Westerveld, Azra Bihorac, Anna Joseph, Alicia Mohr, Lizette V. Duckworth, Frederick A. Moore, Henry V. Baker, Christiaan Leeuwenburgh, Lyle L. Moldawer, Scott Downloaded from Brakenridge and Philip A. Efron J Immunol 2015; 195:2396-2407; Prepublished online 5 August 2015; doi: 10.4049/jimmunol.1500984 http://www.jimmunol.org/ http://www.jimmunol.org/content/195/5/2396 Supplementary http://www.jimmunol.org/content/suppl/2015/08/05/jimmunol.150098 Material 4.DCSupplemental References This article cites 50 articles, 10 of which you can access for free at: by guest on September 23, 2021 http://www.jimmunol.org/content/195/5/2396.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc.
    [Show full text]
  • Aplastic Anemia Pre-HSCT Data (Form 2028)
    Instructions for Aplastic Anemia Pre-HSCT Data (Form 2028) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Aplastic Anemia Pre-HSCT Data Form. E-mail comments regarding the content of the CIBMTR Forms Instruction Manual to: [email protected]. Comments will be considered for future manual updates and revisions. For questions that require an immediate response, please contact your transplant center’s CIBMTR liaison. TABLE OF CONTENTS Key Fields ............................................................................................................. 2 Disease Assessment at Diagnosis ........................................................................ 2 Laboratory Studies at Diagnosis ........................................................................... 5 Transfusion Status from Diagnosis to the Start of the Preparative Regimen ........ 7 Laboratory Findings Prior to the Start of the Preparative Regimen ....................... 8 Aplastic Anemia Pre-HSCT Data Aplastic Anemia is a disease in which the bone marrow does not produce enough red blood cells, white blood cells, or platelets for the body. The disease can be idiopathic, or can be caused by environmental exposure, pharmaceutical or drug exposure, or exposure to viral hepatitis. Symptoms of aplastic anemia include, but are not limited to pallor, weakness, frequent infection, and/or easy bruising. The Aplastic Anemia Pre-HSCT Data Form is one of the Comprehensive Report Forms. This form captures aplastic
    [Show full text]
  • Rituximab: Is It Possible to Link Both Autoimmune Haemolytic Anemia and Aplastic Anemia Regarding the Etiology and Management? Mina T
    icine: O ed pe M n l A a r c e c e n s e s G General Medicine: Open Access Kellani MT, Gen Med (Los Angeles) 2016, 4:3 DOI: 10.4172/2327-5146.1000e110 ISSN: 2327-5146 Editorial Open access Rituximab: Is it Possible to Link Both Autoimmune Haemolytic Anemia and Aplastic Anemia Regarding the Etiology and Management? Mina T. Kelleni* Pharmacology Department, Faculty of Medicine, Minia University, Minia, Egypt *Corresponding author: Kelleni MT, Ph, M, Pharmacology department, aculty of Medicine, Minia niversity, Minia, Egypt, Tel: 201200382422; E- mail: [email protected] Rec Date: June 28, 2016; Acc Date: June 29, 2016; Pub Date: June 30, 2016 Copyright: © 2016 Kelleni MT. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Citation: Mina Kellani T (2016) Rituximab: Is it Possible to Link Both Autoimmune Haemolytic Anemia and Aplastic Anemia Regarding the Etiology and Management? Gen Med (Los Angeles) 4: e110. Editorial References In the past few years, rituximab has been recognized as a safe and 1. Abadie K, Hege KM (2014) Severe refractory autoimmune hemolytic effective emerging treatment for autoimmune hemolytic anemia anemia with five-year complete hematologic response to third course of (AIHA) [1,2]. Rituximab was also considered as a preferred second- treatment with rituximab: a case report. Journal of medical case reports 8: line therapy of warm antibody hemolytic anemia in adults in some 175. major European centers and it was shown that second-line treatment 2.
    [Show full text]
  • AAMDSIF Aplastic Anemia Presentation
    Aplastic Anemia Emma Groarke, MD, FRCPath Staff Clinician, Bone Marrow Failure Service National Heart, Lung, and Blood Institute National Institutes of Health AA MDS 18th May, 2019 Introduction . Aplastic Anemia . Immune mediated . What is it and what causes it? . Diagnosis . Treatment . Immunosuppression . Transplant . Pure Red Cell Aplasia . What is it and what causes it? . Ongoing research 2 A historical disease Aplastic Anemia . Rare blood disorder . 2-3 per million / year . Low blood counts and empty bone marrow . Peak age distributions . 10-25 years old and >60 years old 4 Causes of Aplastic Anemia . Immune system destroying bone marrow cells . “idiopathic” . 70% . Inherited abnormal genes . Telomere diseases . Fanconi anemia . Bone marrow toxins . Rare Young, N. S. (2018). "Aplastic Anemia." N Engl J Med 379(17): 1643-1656. 5 Mechanism of Aplastic Anemia . Immune system attacks the bone marrow . Active lymphocytes (T cells) . Increase in inflammation . Cells die Young, N.S. et al. Blood.2006 6 Aplastic Anemia Young, N. S. (2018). "Aplastic Anemia." N Engl J Med 379(17): 1643-1656. Marrow is “empty” Courtesy of Dr. Stanley Schreier, American Society of Hematology Image Bank 8 How does it affect the patient? . Neutropenia (low white cells) . Risk of infection - If less than 500 – risk of infection - If less than 200 – high risk of infection . Thrombocytopenia (low platelets) . Risk of bleeding - Risk of bleeding with trauma / procedures if <50 - Some risk bleeding <20 - Higher risk bleeding <10 – Platelet transfusion . Anemia (low red cells or hemoglobin) . Red cells carry oxygen in the blood - Symptoms include: - Tiredness - Shortness of breath . If hemoglobin <7 or symptoms - blood transfusion 9 Clonal evolution .
    [Show full text]
  • Laboratory Features of Cutaneous Lupus Erythematosus 313
    CHAPTER 23 Laboratory Features 23 of Cutaneous Lupus Erythematosus Shuntaro Shinada, Daniel J. Wallace Assuming that patients with cutaneous lupus erythematosus (CLE) do not fulfill the American College of Rheumatology criteria for systemic LE (SLE) (Tan et al. 1982), what laboratory features should the clinician look for? Interestingly, there are several. This chapter attempts to elucidate the laboratory abnormalities associated with CLE, the most common being hematologic (anemia and leukopenia), erythrocyte sedi- mentation rate (ESR), antinuclear antibodies (ANAs), and antiphospholipid anti- bodies. These features are compared with those observed in SLE and certain cuta- neous clinical subsets that have been studied. General Approach to Laboratory Testing When a dermatologist, family practitioner, internist, or rheumatologist first sees a patient with CLE, their principal concern should be to rule out evidence of systemic disease. After all, 15% of patients with CLE progress to SLE in 10–15 years of obser- vation (Rowell 1984). In addition to a complete medical history and physical exami- nation, clinical laboratory findings can be very helpful in this regard. Specifically, a blood chemistry panel allows screening for renal or hepatic involvement. Creatine phosphokinase testing assists in ruling out muscle inflammation. Evidence for autoimmune hemolytic anemia or thrombocytopenia is looked for in the complete blood cell count as well as in the lactic dehydrogenase, reticulocyte count, Coombs’ direct antibody testing, serum haptoglobin, and antiplatelet antibodies. A routine urinalysis free of cellular casts or protein makes it highly unlikely that the kidney is involved. Specific autoantibodies, almost never observed in CLE, if found, can suggest central nervous system disease (antiribosomal P,antineuronal), mixed connective tis- sue disease (anti-RNP), or other disease subsets.
    [Show full text]
  • Impaired B-Lymphopoiesis, Myelopoiesis, and Derailed Cerebellar Neuron Migration in CXCR4- and SDF-1-Deficient Mice
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 9448–9453, August 1998 Immunology Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice QING MA*, DAN JONES*†,PAUL R. BORGHESANI†‡,ROSALIND A. SEGAL‡,TAKASHI NAGASAWA§, i TADAMITSU KISHIMOTO¶,RODERICK T. BRONSON , AND TIMOTHY A. SPRINGER*,** *The Center for Blood Research and Department of Pathology, Harvard Medical School, Boston, MA 02115; ‡Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115; §Department of Immunology, Research Institute, Osaka Medical Center for Maternal and Child Health, 840 Murodo-cho, Izumi, Osaka 590-02, Japan; ¶Department of Medicine III, Osaka University Medical School, 2-2 Yamada-oka, Suita, Osaka 565, Japan; and iDepartment of Pathology, Tufts University School of Medicine and Veterinary Medicine, Boston, MA 02111 Contributed by Timothy A. Springer, June 9, 1998 ABSTRACT The chemokine stromal cell-derived factor 1, individuals is associated with the decline of CD41 cells and SDF-1, is an important regulator of leukocyte and hemato- clinical progression to AIDS. poietic precursor migration and pre-B cell proliferation. The SDF-1 and CXCR4 have several unusual features for a receptor for SDF-1, CXCR4, also functions as a coreceptor for chemokine and receptor. First, SDF-1 is extraordinarily con- T-tropic HIV-1 entry. We find that mice deficient for CXCR4 served in evolution, with only one amino acid substitution die perinatally and display profound defects in the hemato- between the human and mouse proteins (10). Based on the poietic and nervous systems. CXCR4-deficient mice have presence of an intervening amino acid between the two severely reduced B-lymphopoiesis, reduced myelopoiesis in N-terminal cysteines, SDF-1 has been grouped with the CXC fetal liver, and a virtual absence of myelopoiesis in bone chemokine subfamily; however, the protein sequence of SDF-1 marrow.
    [Show full text]
  • Not So Benign Hematology: Aplastic Anemia, PNH And
    Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology Disclosures • Dr. Brodsky serves as a Scientific Advisory Board member to: – Alexion Pharmaceuticals – Achillion Pharmaceutical – Apellis Pharmaceuticals • Grant funding: Alexion Organization • Bone Marrow Failure – Aplastic anemia • Is the era of IST coming to an end? – New complement inhibitors for PNH? • Thrombotic Microangiopathies – aHUS • Modified Ham to distinguish aHUS from TTP • Do aHUS patients need lifelong therapy with eculizumab Severe Aplastic Anemia Definitive management • Allogeneic bone marrow transplantation • Immunosuppressive therapy Acquired SAA is an Acute and Chronic Disease Take Home: PIGA Autoimmune attack on stem cells AA PNH Predisposes to clonal escape/malignancy 6pLOH 10~12% DNMT3A ASLX1 Monosomy 7 MDS Severe Aplastic Anemia • First line therapy – BMT • Matched sibling donor • Matched unrelated donor – IST (ATG/CSA) • Refractory Disease (poor response/prognosis) – Eltrombopag – Alternative donor BMT – Androgens – Other IST ATG/CSA: Late complications Rosenfeld et. al, Jama 2003;289: 1130-35 Risk of relapse > 40% in Risk of clonal evolution responders 30% failure-free survival Refractory SAA 2yr mortality approaches 50% • Repeat IST – low response rate • Eltrombopag • BMT – usually from a MUD or alternative donor Eltrombopag for Refractory SAA Desmond et al, Blood 2014 • 43 patients with refractory SAA – 1o endpoint: response at 3mos. in at least 1 linage – Response criteria (e.g, doubling of ANC, decrease in PRBCs) • Results: – 17/43 (40%) at 3 mos – 9/43 (21%) met standard response criteria at 6 mos – 7/43 (16%) trilineage response • Relapse: 3/17 (18%) responders within a year • MDS: 8/43 (16%) within 1 year Responses to eltrombopag by lineage.
    [Show full text]
  • Aplastic Anemia: Diagnosis and Treatment Gabrielle Meyers, MD, and Curtis Lachowiez, MD
    Clinical Review Aplastic Anemia: Diagnosis and Treatment Gabrielle Meyers, MD, and Curtis Lachowiez, MD year. 2,3 A recent Scandinavian study reported that the in- ABSTRACT cidence of aplastic anemia among the Swedish popula- Objective: To describe the current approach to diagnosis tion is 2.3 cases per million individuals per year, with a and treatment of aplastic anemia. median age at diagnosis of 60 years and a slight female 2 Methods: Review of the literature. predominance (52% versus 48%, respectively). This data is congruent with prior observations made in Barcelona, Results: Aplastic anemia can be acquired or associated with an inherited marrow failure syndrome (IMFS), where the incidence was 2.34 cases per million individu- and the treatment and prognosis vary dramatically als per year, albeit with a slightly higher incidence in males between these 2 etiologies. Patients may present along compared to females (2.54 versus 2.16, respectively).4 The a spectrum, ranging from being asymptomatic with incidence of aplastic anemia varies globally, with a dispro- incidental findings on peripheral blood testing to life- portionate increase in incidence seen among Asian pop- threatening neutropenic infections or bleeding. Workup ulations, with rates as high as 8.8 per million individuals and diagnosis involves investigating IMFSs and ruling per year.3-5 This variation in incidence in Asia versus other out malignant or infectious etiologies for pancytopenia. countries has not been well explained. There appears to Conclusion: Treatment outcomes are excellent with modern be a bimodal distribution, with incidence peaks seen in supportive care and the current approach to allogeneic young adults and in older adults.2,3,6 transplantation, and therefore referral to a bone marrow transplant program to evaluate for early transplantation is Pathophysiology the new standard of care for aplastic anemia.
    [Show full text]
  • Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders
    Journal of Clinical Medicine Review Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders Cristiana Bianco 1 , Elena Coluccio 1, Daniele Prati 1 and Luca Valenti 1,2,* 1 Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy; [email protected] (C.B.); [email protected] (E.C.); [email protected] (D.P.) 2 Department of Pathophysiology and Transplantation, Università degli Studi di Milano, 20122 Milan, Italy * Correspondence: [email protected]; Tel.: +39-02-50320278; Fax: +39-02-50320296 Abstract: Anemia is a common feature of liver and bowel diseases. Although the main causes of anemia in these conditions are represented by gastrointestinal bleeding and iron deficiency, autoimmune hemolytic anemia should be considered in the differential diagnosis. Due to the epidemiological association, autoimmune hemolytic anemia should particularly be suspected in patients affected by inflammatory and autoimmune diseases, such as autoimmune or acute viral hepatitis, primary biliary cholangitis, and inflammatory bowel disease. In the presence of biochemical indices of hemolysis, the direct antiglobulin test can detect the presence of warm or cold reacting antibodies, allowing for a prompt treatment. Drug-induced, immune-mediated hemolytic anemia should be ruled out. On the other hand, the choice of treatment should consider possible adverse events related to the underlying conditions. Given the adverse impact of anemia on clinical outcomes, maintaining a high clinical suspicion to reach a prompt diagnosis is the key to establishing an adequate treatment. Keywords: autoimmune hemolytic anemia; chronic liver disease; inflammatory bowel disease; Citation: Bianco, C.; Coluccio, E.; autoimmune disease; autoimmune hepatitis; primary biliary cholangitis; treatment; diagnosis Prati, D.; Valenti, L.
    [Show full text]
  • 10 Maturation and Development of Leucocytes
    MODULE Maturation and Development of Leucocytes Hematology and Blood Bank Technique 10 Notes MATURATION AND DEVELOPMENT OF LEUCOCYTES 10.1 INTRODUCTION The leucocytes develop from the multipotent hematopoietic stem cell which then gives rise to a stem cell committed to formation of leucocytes. Both these cells cannot be identified morphologically by routine methods. The various types of leucocytes are granulocytes (neutrophils, eosinophils and basophils), monocytes and lymphocytes. The three cell types develop separately and accordingly these processes will be discussed separately. OBJECTIVES After reading this lesson, you will be able to: z explain the various stages in the development of leucocytes. z describe the different types of leucocytes seen normally in PBF. 10.2 MYELOPOIESIS This is the process of formation of myeloid cells. It is restricted to the bone marrow after birth. The committed progenitor cell for granulocytes and monocytes is the GM-CFU which proliferates and differentiates to form myeloblast and monoblast. The myeloblast is the earliest morphologically identifiable cell. It is 10-18µm in size. The cytoplasm is scant and basophilic, usually agranular and may contain a few azurophilic cytoplasmic granules in the blast transiting to the next stage 80 HEMATOLOGY AND BLOOD BANK TECHNIQUE Maturation and Development of Leucocytes MODULE of promyelocyte. It has a large round to oval nucleus with a smooth nuclear Hematology and Blood membrane. The chromatin is fine, lacy and is evenly distributed throughout the Bank Technique nucleus. Two-five nucleoli can be identified in the nucleus. The next stage of maturation is the Promyelocyte. It is larger than a myeloblast, 12-20 µm with more abundant cytoplasm which has abundant primary azurophilic granules .
    [Show full text]